A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China

Journal of Digestive Diseases

Volumn 10, Issue 2, 2009, Pages 131-137

  Yao, Guang Bi ^a   Zhu, Mei ^a   Cui, Zhen Yu ^b   Wang, Bao En ^c   Yao, Ji Lu ^d   Zeng, Ming De ^e  

^a Jing'an District Center Hospital   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic hepatitis B; HBeAg seroconversion; Hepatitis B virus (HBV); Lamivudine; YMDD variant

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS E ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINA; CHRONIC HEPATITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERBILIRUBINEMIA; LIVER CANCER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT DURATION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE;

EID: 65449140873     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2009.00375.x     Document Type: Article

References (23)

1. Hepatitis B fact sheet WHO/2004. Hepatitis B. Geneva: World Health Organization, October 2004. Available from URL: http:// www.who.intmedicentres/facsheets/fs204/en
2. Sero-epidemiology survey of hepatifis B infection in China. http:// www.chinaccdc.net.cn/n272442/n3246177/23316.html2008-4-23.
3. Dai ZC, Qi GM. The Epidemiology Characteristics of Viral Hepatitis B in China: Sero-epidemiological Survey in Chinese Population (Part One) 1992-1995. Beijing: Sci Tech Pub. 1997 (in Chinese).
4. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B virus in the United States. N Engl J Med 1999; 341: 1256-63.
5. Lai CL, Chien R, Leung N et al. for the Asian Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
6. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD. Long term efficacy of lamivudine in the treatment of hepatitis B patients. Chinese J Hepatol 1999; 7: 80-3 (in Chinese).
7. Yao GB. Management of hepatitis B in China. J Med Virol 2000; 61: 392-7.
8. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD. Three year clinical trial of lamivudine in the treatment of patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004; 3: 188-93.
9. Lok ASF, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterol 2003; 125: 1714-22.
10. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001; 16 (Suppl.): A60.
11. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD. Four-year long term efficacy of lamivudine in the treatment of hepatitis B patients. Chinese J New Drug Clin Rem 2003; 22: 587-92 (in Chinese).
12. Krajden M, Minor J, Cor KL, Comanor L. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. J Viral Hepatitis 1998; 5: 412-22.
13. Allen M, Gauther J, Des Lauries M et al. Two sensitive PCR-based methods for the detection of hepatitis B virus mutants associated with reduced susceptibility in lamivudine. J Clin Microbiol 1999; 37: 3338-47.
14. Yao GB, Cui ZY, Yao JL et al. Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: A phase IV study. Chin J Hepatol 2003; 11: 103-9 (in Chinese).
15. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatol 2002; 36: 186-94.
16. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatol 2003; 37: 748-55.
17. Yang MY, Yao GB. The effect of the health related quality of life after 2 years treatment of lamivudine in chronic hepatitis B. Chinese J Current Pract Medicine 2002; 1: 47-9. (in Chinese)
18. Yao GB, Alison TM, Huang Y, Jian NX, Yang L. Evaluation of health related quality of life with treatment of lamivudine in chronic hepatitis B. Chinese Hepatol 2003; 8: 3-5. (in Chinese)
19. Liaw YF, Leung N, Kao JH et al. Asia-Pacific Consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008; 2: 263-83.
20. Yuen MF, Fong DYT, Wong DKH et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5 year ideal response. Hepatology 2007; 46: 1695-703.
21. Lok ASF. Navigating the maze of hepatitis B treatments. Gastroenterol 2007; 132: 1586-94.
22. Lampertico P, Viganno M, Meneti E et al. Low resistance to adefovir combined with lamivudine: A 3-year study of lamivudine-resistant hepatitis B patients. Gastroenterol 2007; 133: 1445-51.
23. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistant to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.